Share This

Public company info - Genor Biopharma Holdings Limited , 06998.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Genor Biopharma Holdings Limited, 06998.HK - Company Profile
Chairman YI Qingqing
Share Issued (share) 491,000,000
Par Currency U.S. Dollar
Par Value 2.0E-5
Industry Biotechnology
Corporate Profile Business Summary: The group is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Performance for the year: In the years ended 31 December 2018 and 2019 and the three months ended 31 March 2019 and 2020, the group’s net losses were RMB288.1 million, RMB522.7 million, RMB74.3 million and RMB142.5 million, respectively. Business Review The group’s mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally. Drug candidates that the group have been developing encompass the top three oncology targets and five out of the ten bestselling drugs globally. Since the group’s inception in 2007, the group have been strategically focused on major therapeutic areas with substantial unmet medical needs in oncology, autoimmune and other chronic diseases. For example, the group have developed a systematic and comprehensive development plan for breast cancer-focused therapies, which includes a CDK4/6-targeting drug candidate and an advanced set of HER2-targeting drug candidates, and also for a PD-1-targeting drug candidate targeting multiple oncology indications. In recent years, with research centers built in both Shanghai, China and San Francisco, United States, the group have also been expanding the group’s research and development footprint globally to build and enrich the group’s novel drug pipeline. As of the Latest Practicable Date, the group have leveraged primarily the group’s in-house capabilities in establishing a pipeline of 15 targeted drug candidates with tremendous commercialization potentials in China that cover both proven and novel biological pathways. the group currently have 17 clinical trials ongoing in Asia, with two NDAs expected to be filed with the NMPA, four INDs to be filed with the NMPA and the FDA in the next 12 to 18 months, and one NDA recently accepted for review by the NMPA. In particular, the group have curated six key drug candidates for various oncology, autoimmune and other chronic disease indications. the group’s key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a highly promising RANKL mAb drug candidate. the group also have a strong lineup of cutting-edge bi-specific antibody drug candidates currently in pre-clinical stage, fueled by the group’s differentiated bi-specific mAb antibody platform with Computer-Aided Antibody Design (CAAD) capabilities. The group’s business is backed by the group’s integrated biopharmaceutical platform covering all the key drug development functionalities, including discovery, research, clinical development, CMC (Chemistry, Manufacture and Controls) and business development. the group’s integrated platform enables us to manage the risks of drug development by identifying and addressing potential CMC and clinical barriers early in the development process, which allows us to direct the group’s efforts towards molecules with the best potential to become clinically beneficial and commercially viable drugs. Further, the group have commercialization-ready manufacturing capabilities with quality excellence and enhanced cost efficiencies, boasting concentrated fed-batch and perfusion technologies that allow us to generate higher titer and yield than the conventional technologies, reaching the high-end of the industry range. The group’s core management team members have more than 15 years of industry experience on average with proven track record and a well-balanced combination of expertise spanning research, clinical development, manufacturing, commercialization and financing. the group’s shareholders consist of global and Chinese biotechnology-focused specialist funds and biopharma platforms experienced in supporting and growing biopharmaceutical companies, and the group benefit from their resources and industry expertise. Prospects: To achieve the group’s mission to become a world-class biopharmaceutical leader in research, development, manufacturing and commercialization of innovative therapeutics for patients in China and globally, the group will pursue the following strategies. • Multiple late stage oncology drug candidates targeting top three targets globally • Leading drug candidates for China autoimmune and osteoporosis markets • Robust product pipeline of bi-specific antibody drug candidates with meaningful clinical benefit and market potential • Integrated biopharmaceutical platform • Commercialization-ready manufacturing capabilities with quality excellence and enhanced cost efficiencies • Seasoned management team with substantial industry experience and strong shareholder support

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.